Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Eli Lilly offers $70 a share for Imclone
ImClone had announced that its mystery bidder would be revealed by Wednesday night at 11:59, and now the news is out. Pharma giant Eli Lilly has bid $6.1 billion, at $70 a share, according to a report in the Wall Street Journal. Insiders say Pfizer was also among BMS's competition, although the details of its bid have not be revealed. Eli Lilly has just before midnight tonight to make a decision.
Both Eli Lilly and Pfizer have been vocal about their desire to beef up their biotech pipelines. In a recent speech, Lilly chairman and CEO John Lechleiter (photo) reiterated the company's focus on biologics, saying that biotech drugs would be Lilly's preferred choice from now on. And just yesterday Pfizer announced an R&D revamp, which includes a greater focus on biologics.
- read this report for more
Related Articles:
Eli Lilly out to redesign itself as a biotech
Lilly's Lechleiter: 'We're a biotech'
Merck KGaA eyes ImClone, but isn't mystery bidder
ImClone says mystery bidder will be revealed
Icahn to BMS: Your $62 hostile bid is 'absurd'
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
